The role of treprostinil in the management of pulmonary hypertension

American Journal of Cardiovascular Drugs

Volumn 8, Issue 4, 2008, Pages 213-217

  Skoro Sajer, Nika ^a   Lang, Irene ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Prostacyclin agonists, therapeutic use; Pulmonary hypertension, treatment; Treprostinil, therapeutic use

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; UNIPROST; VASODILATOR AGENT;

BORG DYSPNEA SCORE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; EXERCISE; GRAM NEGATIVE INFECTION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; INJECTION SITE PAIN; INTRAVENOUS CATHETER; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCORING SYSTEM; SURVIVAL; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; SURVIVAL RATE;

EID: 49449096341     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808040-00001     Document Type: Review

References (24)

1. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-9
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44
4. Williams SP, Dorn 2nd GW, Rapoport RM. Prostaglandin i2 mediates contraction and relaxation of vascular smooth muscle. Am J Physiol 1994; 267: H796-803
5. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-21
6. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S
7. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic signifi-cance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-92
8. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-21
9. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11
10. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99: 696-8
11. Barst R, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301
12. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 56S-61S
13. McNulty MJ, Sailstad JM, Steffen RP. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15au81 in the anesthetized beagle dog. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 159-66
14. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4
15. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129: 1636-43
16. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-82
17. Vachiery JL, Hill N, Zwicke D, et al. Transitioning from i.v: epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121: 1561-5
18. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J 2006; 28: 1195-203
19. Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007; 5: 483-9
20. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44: 209-14
21. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129: 683-8
22. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1586-9
23. Sitbon O, Manes A, Jais X, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007; 49: 1-5
24. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension: seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56: 170-2